Nephrology · Clinical Guide ·
Every minute, your two kidneys filter approximately 1.3 litres of blood, stripping out metabolic waste, balancing electrolytes, regulating blood pressure, and generating hormones that govern red blood cell production and bone health. They perform this feat 24 hours a day, with a spare capacity so generous that most people can lose more than half their kidney function before they notice a single symptom. That biological insurance policy, remarkable as it is, is also one of the great clinical hazards of kidney disease: by the time a patient feels unwell, the damage is frequently far advanced. Understanding how chronic kidney disease (CKD) progresses through its five recognised stages is therefore not merely an academic exercise — it is one of the most practical things a person can know.
The numbers behind this disease are sobering. A 2021 Global Burden of Disease analysis found that CKD affected approximately 673 million people worldwide, causing 1.5 million deaths that year, with the burden driven primarily by metabolic risk factors.[1] The condition already ranks among the fastest-rising causes of death globally, and epidemiologists at Frontiers in Endocrinology project that if current trends in diabetes, hypertension, and aging continue unchecked, CKD could become the fifth leading cause of death globally by 2040.[2] In the United States alone, the National Kidney Foundation estimates that 37 million adults live with the disease, the majority of whom are undiagnosed. Yet the trajectory of CKD is not fixed. Early identification, appropriate medical therapy, and lifestyle modification can genuinely slow and sometimes stabilise disease progression — and the earlier these interventions begin, the more kidney function can be preserved.
FoundationHow Kidney Function Is Measured and Staged
The modern staging framework for chronic kidney disease was first codified by the Kidney Disease Outcomes Quality Initiative (KDOQI) in 2002 and then significantly refined by the international body Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. The most recent and comprehensive update — the KDIGO 2024 Clinical Practice Guideline — builds on that framework with new evidence from wider population studies and a new generation of disease-modifying therapies.[3] Under this system, CKD is defined as abnormalities in kidney structure or function lasting more than three months, with implications for health. Two measurements sit at the heart of every clinical assessment.
The first is the estimated Glomerular Filtration Rate (eGFR), measured in millilitres per minute per 1.73 m² of body surface area. It reflects how efficiently the kidneys are filtering blood and is calculated from serum creatinine levels, adjusted for age, sex, and race using validated equations. The KDIGO 2024 guidelines place particular emphasis on combining creatinine with cystatin C — a second biomarker — to produce a more accurate combined eGFRcr-cys estimate, as the CKD Prognosis Consortium data confirm this dual-marker approach is superior at distinguishing risk stages.[4] The second critical measurement is the urine albumin-to-creatinine ratio (UACR), which detects albumin — a protein that healthy kidneys retain but damaged ones leak — in the urine. KDIGO 2024 recommends assessing both eGFR and UACR at least annually in all CKD patients, with more frequent monitoring in those at higher risk.[5] Together, these two numbers define not just the stage of CKD but its trajectory and prognosis.
AetiologyWhat Causes Kidney Disease to Begin
Chronic kidney disease does not arise in a vacuum. In the vast majority of cases, it is the downstream consequence of conditions that damage the kidney's delicate filtration architecture over years or decades. Globally, diabetes mellitus is the single leading cause, accounting for the largest share of CKD burden worldwide, with type 2 diabetes driving an especially steep increase.[6] In the United States, among people with diagnosed diabetes, the prevalence of CKD stages 3–4 reaches 24.5%, compared to just 4.9% in non-diabetics.[7] Diabetes injures the kidney through a combination of chronic hyperglycaemia, hyperfiltration injury, and progressive thickening of the glomerular basement membrane, eventually leading to diabetic nephropathy — the most common form of CKD entering dialysis programmes worldwide.
Hypertension is the second major culprit, both as a primary cause and as an accelerator of decline from other causes. Sustained high blood pressure damages the small arteries supplying the kidney's glomeruli, reducing blood flow and triggering scarring processes. The relationship is bidirectional: CKD itself raises blood pressure by impairing sodium excretion and activating the renin-angiotensin-aldosterone system, creating a vicious cycle that accelerates both conditions simultaneously. Beyond these two dominant causes, glomerulonephritis (immune-mediated inflammation of the kidney filters), polycystic kidney disease (a genetic condition producing fluid-filled cysts), recurrent urinary tract infections, certain analgesic medications, and — increasingly recognised — APOL1 gene variants that confer substantially elevated CKD risk in people of Black African ancestry all contribute to the global burden.[8] In parts of Central America, South Asia, and Sri Lanka, a form of CKD of unknown aetiology (CKDu) affecting agricultural workers has emerged as a major public health crisis.
The principal primary cause of CKD globally is diabetes. The rising prevalence of obesity and diabetes, in addition to the ageing of the global population, is likely to lead to a rising burden of CKD.— The Lancet, Global Burden of CKD Study 2023
Stage G1Kidney Damage with Normal or Increased Function
At Stage G1, the kidneys are filtering at normal or even elevated rates — a paradox that reflects the kidney's capacity for compensatory hyperfiltration in the face of early injury. The eGFR sits at 90 or above, meaning kidney function by this metric appears intact. What flags the problem is not the filtration rate itself but structural damage detectable through the urine: albuminuria (protein in the urine), blood in the urine (haematuria), abnormalities on kidney imaging such as ultrasound, or pathological changes found on biopsy. A patient might have a slightly foamy quality to their urine — a sign that protein is slipping through damaged glomeruli — but most will notice nothing at all. This is the stage at which CKD is most curable in its underlying causes and most amenable to intervention that prevents progression entirely. A person with early diabetic nephropathy identified here, placed on optimal blood pressure control and an ACE inhibitor or ARB, has a genuinely good chance of preserving that eGFR for many years.
Stage G2Mildly Reduced Kidney Function
Stage G2 represents a mild but real reduction in kidney function, with the eGFR falling between 60 and 89. At this level, the kidneys are still performing the great majority of their work, and most people remain asymptomatic. The diagnosis is almost always a laboratory finding — typically identified during a health check, workup for diabetes or hypertension, or blood and urine tests ordered for other reasons. The clinical importance of Stage G2 lies in its trajectory: without intervention, a patient whose eGFR is declining even slowly will eventually move to more advanced stages. The key question clinicians ask is not "what is your eGFR today?" but "how fast is it changing?" A rapid eGFR decline of 5 mL/min/1.73 m² per year — known as rapid progression — substantially elevates the risk of reaching kidney failure within a decade, and studies using the KDIGO 2024 framework confirm that elevated systolic blood pressure, anaemia, diabetes, and moderately increased albuminuria are all independent predictors of this accelerated decline.[9]
Stage G3Moderately Reduced Kidney Function — The Watershed Stage
Stage G3 is the watershed of chronic kidney disease. It is subdivided into G3a (eGFR 45–59) and G3b (eGFR 30–44), a distinction that matters because the risk of reaching kidney failure differs substantially between them. This is the stage at which symptoms begin to emerge in a meaningful proportion of patients — not because the kidneys have stopped working, but because their reserve has been consumed. Fatigue is the most common complaint, driven partly by the early anaemia of CKD: damaged kidneys produce insufficient erythropoietin, the hormone that stimulates red blood cell production, and the resulting mild anaemia saps energy and exercise tolerance. Fluid retention may produce ankle oedema. Sleep architecture frequently deteriorates. And the metabolic consequences of reduced clearance — mild elevations of phosphate, early disruptions of calcium and parathyroid hormone homeostasis — begin to affect bone metabolism in a syndrome known as CKD-mineral and bone disorder (CKD-MBD).
From a treatment perspective, Stage G3 is now one of the most pharmacologically active periods in the disease's management. The landmark trials CREDENCE, DAPA-CKD, and EMPA-KIDNEY have firmly established that SGLT2 inhibitors — originally developed as glucose-lowering agents for type 2 diabetes — produce significant and durable reductions in the rate of eGFR decline, cardiovascular events, and kidney failure in patients with CKD and albuminuria, irrespective of diabetic status.[10] The KDIGO 2024 guideline gives a Grade 1A recommendation (its highest level of evidence) for SGLT2 inhibitor use in patients with type 2 diabetes and CKD with an eGFR of 20 or above.[11] This marks a transformation in nephrology practice: for the first time, there are disease-modifying therapies that can genuinely alter the natural history of CKD, not merely manage its complications.
Stage G4Severely Reduced Kidney Function — Preparing for Replacement
By Stage G4, the kidneys have lost the majority of their functional nephrons and are operating at 15–29% of normal capacity. Symptoms are now clinically apparent in most patients, though their severity varies considerably with the individual's compensatory reserves, dietary habits, and comorbid conditions. Waste products such as urea and creatinine accumulate in the blood, producing a syndrome called uraemia in its incipient form: nausea, loss of appetite, metallic taste in the mouth, generalised malaise, and a characteristic itching of the skin caused by urate crystal deposition. Anaemia typically requires active treatment, and the bone mineral disorder worsens, placing patients at elevated risk of fractures and vascular calcification. Perhaps most consequentially, cardiovascular risk is dramatically elevated at this stage — patients with Stage G4 CKD are statistically more likely to die from a cardiovascular event than to reach dialysis.
Stage G4 is also the planning stage. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recommends that patients begin comprehensive education about their kidney replacement therapy options well before they reach Stage 5.[12] This education covers three pathways: haemodialysis (in a centre or at home), peritoneal dialysis, and kidney transplantation. If haemodialysis is the likely route, surgical creation of a vascular access — either an arteriovenous fistula or a graft — should be planned well in advance, as a functional fistula typically requires 3–6 months to mature. For those who are transplant candidates, referral to a transplant centre should occur at Stage G4 at the latest, enabling evaluation and potential living-donor identification before dialysis becomes necessary.
Stage G5Kidney Failure — End-Stage Renal Disease
Stage G5 — kidney failure, also known as end-stage kidney disease (ESKD) or end-stage renal disease (ESRD) — is reached when the eGFR falls below 15, meaning 85–90% of kidney function is permanently lost.[13] At this point, the kidneys can no longer sustain life independently. Waste products accumulate to toxic levels, electrolyte balance collapses, fluid overloads the circulation and fills the lungs, and the neurological system begins to falter under the burden of uraemic toxins. Without intervention, Stage G5 CKD is fatal.
The treatment options at Stage G5 are well defined. Haemodialysis passes the patient's blood through an external dialysis machine that filters waste and fluid across a semipermeable membrane, typically requiring sessions of three to four hours three times per week at a dialysis centre, or more frequent shorter sessions for home haemodialysis. Peritoneal dialysis uses the peritoneal membrane — the lining of the abdominal cavity — as a natural filter, with dialysis fluid instilled and drained through a surgically placed catheter, enabling the patient to perform treatments at home, often overnight via an automated device. Kidney transplantation remains the most effective treatment for most eligible patients: a successful transplant from a living or deceased donor provides kidney function that dialysis can only partially replicate, and long-term survival data consistently favour transplanted patients over those maintained on dialysis. The National Kidney Foundation emphasises that while kidney failure has no cure, treatment makes a longer and productive life possible.[14]
A fourth option, sometimes overlooked in clinical conversations, is conservative management without dialysis. For elderly or frail patients with significant comorbidities, the demands of dialysis — time, access complications, cardiovascular stress — may not improve quality of life and may even shorten it. The NIDDK describes conservative management as a legitimate, values-aligned choice that focuses on symptom control and quality of life rather than life prolongation at all costs.[15] These conversations are among the most important and most challenging in nephrology, requiring a frank partnership between the patient, their family, and the multidisciplinary care team.
TreatmentThe Modern Therapeutic Arsenal Against CKD Progression
The past decade has seen an extraordinary expansion in the pharmacological tools available to slow CKD progression, and the KDIGO 2024 guideline reflects a field transformed by large randomised trials. The management strategy for most patients now involves layering several drug classes, each addressing a different mechanism of kidney injury.[3]
Beyond medications, the lifestyle foundations remain critically important at every stage. Sodium restriction (targeting less than 2 g sodium per day) reduces blood pressure and fluid retention. A kidney-appropriate diet managed with a renal dietitian — moderating protein, potassium, and phosphate intake according to stage — protects residual function and avoids the metabolic complications of advanced CKD. Regular physical activity, smoking cessation, and weight management each contribute independently to slowing eGFR decline. The Cleveland Clinic and the Mayo Clinic both emphasise that nephrology care is most effective when integrated into a comprehensive lifestyle programme.[16]
MonitoringSurveillance, Complications, and the Importance of Cardiovascular Risk
One of the most important — and sometimes overlooked — clinical realities of CKD is that the kidneys do not fail in isolation. Their progressive dysfunction sets in motion a cascade of systemic complications that span every organ system. Anaemia, as discussed, affects most patients by Stage G3. Metabolic acidosis — a buildup of acid in the blood as the kidneys lose their buffering capacity — accelerates muscle wasting and bone loss. Disordered mineral metabolism increases cardiovascular calcification. And throughout all stages, CKD functions as an independent and powerful risk factor for heart attack, stroke, heart failure, and cardiovascular death. At Stage G5, the National Kidney Foundation notes that patients carry the highest possible cardiovascular risk category, even if their urine albumin is relatively low.[17]
The KDIGO 2024 framework introduces refined "heat-maps" combining eGFR categories with albuminuria categories to estimate overall risk more precisely than either measure alone, and it recommends using validated risk equations — such as the Kidney Failure Risk Equation — to calculate each individual's absolute probability of reaching kidney failure within two and five years. These probability estimates are not meant to frighten patients but to guide the intensity of follow-up, the urgency of referral decisions, and the timing of conversations about kidney replacement therapy preparation. Monitoring frequency for eGFR and UACR should be at least annual for all CKD patients and may be as frequent as three to four times per year for those with rapidly progressing disease or those who have recently changed medications.[5]
CareWhen to Seek Specialist Care and What to Expect
The question of when a primary care physician should refer a patient to a nephrologist is one of the most practically important in CKD management. The KDIGO 2024 guidelines provide clearer and more actionable referral thresholds than their 2012 predecessors. Referral is recommended for patients with an eGFR below 30 (Stage G4), for those with significant albuminuria (UACR above 300 mg/g), for patients with rapid eGFR decline, and for any patient in whom the cause of CKD is uncertain or in whom specialist interventions — including kidney biopsy, immunosuppressive therapy, or advanced metabolic management — are likely to be beneficial. For patients approaching Stage G5, multidisciplinary care involving a nephrologist, renal dietitian, social worker, and transplant coordinator is the standard of care.[3]
For the patient themselves, engaging actively with their care team at every stage is the single most important action. CKD is a long-term condition managed in partnership — decisions about dialysis modality, transplant candidacy, dietary adjustments, and medication regimens all benefit enormously from an informed and engaged patient. Resources such as the National Kidney Foundation, the American Kidney Fund, and the NIDDK all offer free, medically reviewed educational materials that can help patients and families understand what to expect and what questions to ask. The most important question, at any stage, remains simple: how fast is this progressing, and what can we do right now to slow it down?
ConclusionThe Trajectory Is Not Fixed
Chronic kidney disease is not a verdict. It is a process — one that unfolds over years or decades, through five recognisable stages, with warning signs that become increasingly hard to miss as it advances. The tragedy of CKD, historically, was that by the time those warning signs were felt, the window for meaningful intervention had often passed. The promise of modern nephrology, underpinned by the KDIGO 2024 framework and a new generation of disease-modifying therapies, is that this trajectory can be interrupted. SGLT2 inhibitors, ACE inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid antagonists, used together under careful medical supervision, represent the first genuine ability to meaningfully slow the march of this disease across its early and middle stages. Combined with rigorous blood pressure control, lifestyle modification, and regular monitoring, the evidence is clear: the five stages of CKD need not flow inevitably from one to the next.
That possibility, though, depends entirely on awareness — on patients knowing their kidney numbers, on clinicians screening those at risk, and on healthcare systems investing in the early detection and early treatment that cost far less, in human and financial terms, than dialysis units and transplant lists. The kidneys filter quietly, invisibly, without complaint — until, one day, they cannot. The best time to intervene is always before that day arrives.
Clinical References & Sources
- Kidney Disease Burden & Risk Factors, Global Burden of Disease 2021. BMC / Frontiers in Medicine / PMC. PMC12366504. 2021 data: 673 million prevalent cases, 1.5 million deaths.
- Global Burden of CKD 1990–2021: Systematic analysis. Frontiers in Endocrinology. 10.3389/fendo.2025.1526482. Projection: CKD as 5th leading cause of death by 2040.
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney International. S0085-2538(23)00766-4. April 2024.
- NephJC Summary: KDIGO 2024 CKD Guidelines Part 1 — eGFR, cystatin C, albuminuria. NephJC.com. January 2025.
- KDIGO 2024 CKD Guideline Executive Summary (PDF). Monitoring frequency, risk equations, and referral thresholds. KDIGO.org.
- Global, Regional, and National Burden of CKD due to Diabetes Mellitus 1990–2021. Frontiers in Endocrinology. 10.3389/fendo.2025.1513008. Type 2 diabetes as leading cause.
- Epidemiology of CKD: An Update 2022. PMC. PMC9073222. CKD prevalence in diabetics 24.5% vs 4.9% in non-diabetics.
- Global, Regional, and National Burden of CKD 2023. The Lancet. PIIS0140-6736(25)01853-7. APOL1 genetics; CKD of unknown aetiology.
- Predictors of Rapid eGFR Decline in CKD Stages G1–G4 — KDIGO 2024 framework. PMC. PMC12667306. 2025.
- SGLT2 Inhibitor Use in CKD: Supporting Cardiovascular, Kidney, and Metabolic Health. Kidney Medicine. S2590-0595(24)00062-1. FDA approvals of canagliflozin and dapagliflozin for CKD.
- KDIGO 2024 Recommendations on SGLT2 Inhibitors (Grade 1A). Executive Summary, KDIGO. KDIGO.org.
- Choosing a Treatment for Kidney Failure. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NIDDK.gov. Updated October 2025.
- Kidney Failure (ESRD) — Symptoms, Stages & Treatment. National Kidney Foundation. kidney.org. Updated 2025.
- Stage 5 CKD: Kidney Failure and Treatment Options. National Kidney Foundation. kidney.org. Updated 2025.
- Conservative Management for Kidney Failure. NIDDK. NIDDK.gov.
- Chronic Kidney Disease — Diagnosis and Treatment. Mayo Clinic. MayoClinic.org. December 2025. Also: Cleveland Clinic. ClevelandClinic.org. January 2026.
- Stage 5 CKD and Cardiovascular Risk. National Kidney Foundation. kidney.org.
- KDOQI US Commentary on KDIGO 2024 CKD Guidelines. American Journal of Kidney Diseases. S0272-6386(24)00977-6. November 2024.
0 Comments